Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?


Significant advances in treatment and monitoring for patients with chronic myeloid leukemia have occurred over the last decade. With the introduction of the tyrosine kinase inhibitor imatinib, long-term outcomes have improved and new challenges, such as resistance, including mutations, have emerged. Research efforts into mutational analysis have intensified… (More)
DOI: 10.1634/theoncologist.2010-0297


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.